FDA Brief

Warning letters Food

FDA warning letter to

Saffron Health Sciences

High riskIssued Nov 18, 2021Posted Nov 30, 2021Division of Human and Animal Food Operations East II

FDA warned Saffron Health Sciences that Crocin Rich supplements were unapproved new drugs promoted with disease and COVID-19 claims.

What happened

In November 2021, FDA reviewed the company’s website, Facebook page, and Amazon store pages. FDA found claims that Crocin Rich, Crocin Rich II, and Crocin Rich Plus treat or prevent diseases including Alzheimer’s, multiple sclerosis, stroke, eye disease, depression, and COVID-19. FDA said these claims made the products drugs and new drugs requiring approval.

What FDA found

  1. Website, Amazon, and Facebook claims showed the Crocin products were intended to treat or prevent diseases such as Alzheimer’s, multiple sclerosis, stroke, eye disease, depression, and COVID-19.

    Section 201(g)(1)(B) of the Act [21 U.S.C. § 321(g)(1)(B)]
  2. The products are new drugs because they are not generally recognized as safe and effective for those uses.

    Section 201(p) of the Act [21 U.S.C. § 321(p)]
  3. The company introduced or delivered the new drugs into interstate commerce without FDA approval.

    Sections 301(d) and 505(a) of the Act [21 U.S.C. § 331(d), 355(a)]
  4. The products lack adequate directions for use because their intended diseases cannot be safely self-diagnosed or self-treated by a layperson.

    Section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]; 21 CFR 201.5
  5. The products are therefore misbranded, and selling them violates the Act.

    Section 301(a) of the Act [21 U.S.C. § 331(a)]

What FDA wants

FDA asks the company to notify it in writing within 15 working days of steps taken to address the violations and prevent recurrence, with supporting documents, or explain any delay. FDA also requests immediate action to stop selling unapproved products for COVID-19.

Who should pay attention

  • supplement brands making disease-treatment claims
  • retailers and online marketplaces selling similar supplement products
  • firms marketing saffron or crocin products with health claims

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk